Skip to main content
News CANTAR 04.2022
© Colourbox

News categories: Honors & Funding

ImmunoSensation participates in research network CANTAR

CANTAR (CANcer TARgeting) research network funded with 19.4 million euros

The new research network CANTAR (CANcer TARgeting) in the field of oncology aims to develop new chemical substances to identify specific driving pathways of cancer and to explore how cancer can "escape" the immune system. The lead partner is the University of Cologne, with Humboldt Professor Dr. Henning Walczak of the Center for Biochemistry as designated spokesperson. ImmunoSensation2 Member Prof. Dr. Michael Hölzel, director of the Institute for Experimental Oncology at the University Hospital Bonn, is involved. CANTAR is funded with a total of 19.4 million euros for the funding period.

The network bundles highly complementary knowledge available in NRW and builds on already established collaborations among the partners. It pursues a holistic approach in which researchers from chemistry, biology and medicine work together in a way that is unique in Europe. The focus is on the discovery and development of substances that act specifically on cancer cells and spare normal tissue. In addition, active substances are being developed that intervene in cancer-specific metabolic processes or make tumor cells more visible to the patient's own immune system. CANTAR bridges the gap between basic research and translational clinical cancer research.

The University of Duisburg-Essen, TU Dortmund University, the Universities of Bonn and Düsseldorf, RWTH Aachen University, the German Center for Neurodegenerative Diseases in Bonn and the Max Planck Institute of Molecular Physiology in Dortmund are involved as co-applicants.


Contact

Prof. Michael Hölzel

Institute of Experimental Oncology

Medical Faculty, University of Bonn

University Hospital of Bonn

Sigmund-Freud-Strasse 25

53127 Bonn

michael.hoelzel@ukb.uni-bonn.de

Related news

Kerstin Ludwig

News categories: Honors & Funding

Genome data to improve diagnosis and treatment of long Covid

Despite the many advances, there are still major gaps in the care of patients with long-term and post-COVID. The Institute of Human Genetics at the UKB in Bonn now begins a genomLC study as part of a BMG funding priority. The researchers want to help speed up the diagnosis of long- and post-COVID and identify possible biomarkers that could possibly also differentiate between subgroups of the diseases. To this end, the genomic data of those affected is being analyzed as part of a study using blood samples. The project is funded by the Federal Ministry of Health (BMG) with 1.34 million euros.
View entry
Reckzeh News

News categories: Honors & Funding

Creating Personalized Cancer Treatments

Bonn researchers aim to improve colon cancer treatment using 3D organoids and digital twins. Funded by the Federal Ministry of Education and Research (BMBF), a collaborative project involving the University of Bonn, the company ESQlabs and the University Hospital Bonn is seeking to refine the therapy recommendations given to colon cancer patients. To this end, “ISPOT-K” is merging organoids taken from patients with the power of digital twin technology.
View entry
Prof. Dr. Valentin Schäfer

News categories: Honors & Funding

Valentin Schäfer appointed to Specialized Ethics Committee

Prof. Valentin S. Schäfer, Head of the Section of Rheumatology at the University Hospital Bonn (UKB) and researcher at the University of Bonn, has been appointed to the newly created Specialized Ethics Committee for Special Procedures by State Secretary Dr. Thomas Steffen at the Federal Ministry of Health. The committee, which is based at the Federal Institute for Drugs and Medical Devices (BfArM), will begin its work on July 1, 2025 and is responsible for the ethical evaluation of complex clinical trials.
View entry

Back to the news overview